ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 0.0%

Gross margin was 0.0% in Q3 FY2026, down 92.2 pp from a year earlier. On a trailing-twelve-month basis it was 64.9%, down 27.0 pp year over year. Over 3 fiscal years it narrowed by 6.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
0.0%-90.8 pp QoQ
Last fiscal yearDec 2025
91.7%+0.2 pp YoY
LTMSep 2026
64.9%-27.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-92.2 pp——
1 year+0.2 pp——
3 years-6.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
91.7%
Year-over-year change
+0.2pp

Gross Margin vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Sep 2026 gross margin of 64.9% is the lowest of the 4 companies compared; the peer median is 93.2%.
  • Its year-over-year change of -27.0 pp is the lowest of 3, against a peer median of +0.4 pp.
  • Over three fiscal years its change of -6.3 pp compares with a peer median of +3.2 pp.
ACAD Competitors Peer median
Gross Margin for ACAD and competitors
Company Period LTM level YoY 3-year change
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202695.0% ——
AXSMAxsome Therapeutics, Inc.LTM Jun 202693.2% +1.8 pp+3.0 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202664.9% -27.0 pp-6.3 pp
PRAXPraxis Precision Medicines, Inc.FY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ACAD) 93.2%+0.4 pp+3.2 pp

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.15M517.24M726.44M957.8M1.07B
Cost of Revenue19.14M10.17M45.73M81.84M89M
Gross Profit465M507.07M680.71M875.96M982.51M
Gross Margin96.0%98.0%93.7%91.5%91.7%
Research & Development239.42M361.58M351.62M303.25M328.8M
Selling, General & Admin396.03M369.09M402.47M488.43M548.89M
Operating Expenses635.44M730.67M754.09M645.16M877.7M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
EBITDA(164.18M)(211.42M)(45.48M)100.16M150.66M
EBITDA Margin-33.9%-40.9%-6.3%10.5%14.1%
Operating Income(170.44M)(223.6M)(73.38M)230.79M104.81M
Operating Margin-35.2%-43.2%-10.1%24.1%9.8%
Interest Income591K6.61M17.23M25.46M31.72M
Interest Expense00000
Other Income / Expenses2.92M10.15M22.34M27.28M34.09M
Income Before Tax(167.52M)(213.44M)(51.04M)258.08M138.9M
Pre-Tax Margin-34.6%-41.3%-7.0%26.9%13.0%
Income Tax Expense351K2.53M10.25M31.62M(252.1M)
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (Basic)(1.05)(1.34)(0.37)1.372.32
EPS (Diluted)(1.05)(1.34)(0.37)1.362.29
Weighted Avg Shares160.49M161.68M163.82M165.72M169.34M
Weighted Avg Shares (Diluted)160.49M161.68M163.82M166.36M171.36M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.